Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.3K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.3K
Cancer Survival Analysis01:21

Cancer Survival Analysis

342
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
342
  1. Home
  3. Relationship Between Prostate-specific Antigen, Alkaline Phosphatase Levels, And Time-to-tumor Shrinkage: Understanding The Progression Of Prostate Cancer In A Longitudinal Study.
  1. Home
  3. Relationship Between Prostate-specific Antigen, Alkaline Phosphatase Levels, And Time-to-tumor Shrinkage: Understanding The Progression Of Prostate Cancer In A Longitudinal Study.

Related Experiment Video

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

650

Relationship between prostate-specific antigen, alkaline phosphatase levels, and time-to-tumor shrinkage:

Madiha Liaqat1, Rehan Ahmad Khan1, Florian Fischer2

  • 1College of Statistical and Actuarial Sciences (CSAS), University of the Punjab, Lahore, Pakistan.

BMC Urology
|July 3, 2024

View abstract on PubMed

Summary
This summary is machine-generated.
Keywords:
Alkaline phosphataseBiomarkerJoint modelProstate cancerProstate-specific antigen

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K

Related Experiment Videos

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
07:34

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking

Published on: November 17, 2023

650
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.2K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.6K

This study introduces a new joint model to analyze prostate-specific antigen and alkaline phosphatase in prostate cancer, improving predictions with missing data. The model reveals associations between these biomarkers and tumor shrinkage, aiding disease progression understanding.

Area of Science:

  • Oncology
  • Biostatistics
  • Biomarker Research

Background:

  • Prostate cancer progression involves complex interactions between biomarkers like prostate-specific antigen (PSA) and alkaline phosphatase (ALP).
  • Understanding the temporal dynamics of these biomarkers and their relationship with tumor shrinkage is crucial for effective disease management.
  • Existing models often struggle with missing covariate data, limiting their clinical utility.

Purpose of the Study:

  • To develop and validate a novel joint model for analyzing longitudinal PSA and ALP data alongside time-to-tumor shrinkage in prostate cancer.
  • To accurately estimate biomarker associations and predict disease progression, particularly in the presence of missing covariate data.
  • To provide a robust statistical framework for integrating multiple data types in prostate cancer research.

Main Methods:

  • A shared parameters joint model was employed for bivariate longitudinal biomarkers (PSA, ALP) and event time data (tumor shrinkage).
  • The model effectively handles missing covariate data, enhancing estimation accuracy.
  • Incorporated baseline patient characteristics and longitudinal biomarker data for comprehensive analysis.

Main Results:

  • A significant association was identified between PSA and ALP levels concerning time-to-prostate cancer tumor shrinkage.
  • The joint model demonstrated robust performance, providing accurate estimates even with missing data.
  • Shared parameters between longitudinal biomarkers and event times were consistently non-zero, indicating strong interdependencies.

Conclusions:

  • The proposed joint model effectively integrates longitudinal PSA, ALP, and tumor status for valuable insights into prostate cancer progression.
  • The model's ability to handle missing data and accurately capture complex biomarker dynamics enhances its clinical applicability.
  • This approach offers a promising tool for improving prognostic capabilities and clinical decision-making in prostate cancer management.